To the Editor In their study published recently in JAMA Oncology, Tarras and colleagues1 analyzed honoraria and other payments provided to oncologists from 2014 to 2019 in the US. They demonstrated that financial conflicts of interest (FCOIs) have not been showing a decreasing trend even after inception of the Open Payments Program. In Japan, we initiated a similar transparency initiative with investigative journalists.2 From that standpoint, we would be grateful if the authors could respond to the following 2 concerns.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Hashimoto T, Ozaki A, Tanimoto T. Industry Payments to Medical Oncologists. JAMA Oncol. 2021;7(7):1072–1073. doi:10.1001/jamaoncol.2021.1287
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.